Jiri Flogel / Shutterstock.com
The Court of Justice of the European Union (CJEU) has clarified when pharmaceutical patent owners may rely on the Specific Mechanism to prevent parallel imports of their products.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
CJEU, Merck, Sigma, parallel imports, specific mechanism, patent